In:
CNS Oncology, Future Medicine Ltd, Vol. 8, No. 2 ( 2019-06-01), p. CNS32-
Abstract:
Aim: To assess the efficacy and safety of alternative fotemustine administration schedule in elderly patients with recurrent glioblastoma. Patients & methods: Patients aged 〉 65 years with recurrent glioblastoma received fotemustine (80 mg/m 2 ; days 1, 15, 30, 45 and 60, and subsequently every 4 weeks). Primary end point was progression-free survival (PFS) rate at 6 months. Main secondary end point was safety. Results: 58 patients were enrolled at two centers. PFS at 6 months was 47% (27 patients) and overall response rate was 29%. Median PFS and survival were 6 and 7 months, respectively, and longer in responders versus nonresponders. No grade 3–4 hematological toxicities occurred. Conclusion: The alternative fotemustine administration schedule was an effective and safe treatment for recurrent glioblastoma in elderly patients.
Type of Medium:
Online Resource
ISSN:
2045-0907
,
2045-0915
DOI:
10.2217/cns-2019-0004
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2019
detail.hit.zdb_id:
2692808-5